
# occupationalBrainNets

    Markdown adaptation of [Jessica Flannery's template](https://osf.io/6juft/). Slightly modified section headers to more closely match OSF registration. 

    Recommendations of fMRI details come from Nichols et al., 2016; Poldrack et al., 2008.

    For extended checklist guidelines for this section following data analysis, see PHBM COBIDAS report Nichols et al., 2016. 

    See also [this](https://osf.io/ery2q/) table format put together by Cassandra Gould van Praag that can be helpful to check that no methods item has been overlooked.


    ## Goal of extended fMRI preregistration template
    ---

    The goal of this template is to provide sufficient information in preregistration for fMRI data design to increase reproducible reporting practices. 

    Text was adopted from the OSF preregistration challenge template to include the details important for fMRI psychology design. OSF template is retained in some areas and edited in other areas to incorporate both prior published templates and guidelines (Nichols et al., 2016; Poldrack et al., 2008; van‚Äôt Veer & Giner-Sorolla, 2016). 

    https://www.biorxiv.org/content/early/2016/05/20/054262 
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2287206/
    https://www.sciencedirect.com/science/article/pii/S0022103116301925 

    Quick notes:
    All prompts and tables can be used to fill in as it, or as a checklist of information you include for text for that section or checklist for attached files (e.g., json file of scan parameters). Tip: Using it as a checklist will allow you to write these sections as they will appear in your future paper.

    If a certain table/section does not apply, can just state ‚ÄúN/A.‚Äù 

    This is also a base template and will not be sufficient for every type of fMRI analysis. If your methods require additional checklists, please include!


# Study information 
---

## Title: Characterising neural network markers of occupational wellbeing.
---

## Authors: Raul Duke, Charlotte Rae.
___


## Introduction
---

    This can be as complete as you like, but at least a brief introduction is  suggested to help to ensure literature review is done prior to hypotheses and help ensure your hypotheses are properly informed based on the literature. 

Whether we have a job or not is the third biggest factor associated with our wellbeing, after mental and physical health, and personal relationships (What *Works Wellbeing*$^1$). At the same time, the nature of our work, including hours worked, shift patterns, and commuting to the workplace are strong influences on the wellbeing of those in employment (*TUC*$^2$). Furthermore, in 2018-19, 13 million working days were lost to stress, depression and anxiety, with poor mental health the single biggest cause of all sick leave last year: 25% of these days lost to stress are directly attributable to work overload (*Labour Force Survey*, 2018-193$^3$). Occupational factors clearly play a major public health role both in- and out-of employment. However, the neural mechanisms by which such occupational factors influence subjective wellbeing, and engender vulnerability to mental health symptoms, are less well understood. This means that we do not fully understand why some people become unwell as a result of occupational issues, while others remain unaffected.

This project aims to characterise the associations between occupational factors (employment status, hours worked, shift work, commuting) and neural network function (fMRI), and the consequences for wellbeing and mental health using the UK Biobank dataset(UKBiobank$^4$). A major benefit of this dataset is the sample size, far larger than any experimental intervention study in a workplace setting could achieve. This will permit population-level inferences on the associations between occupational factors and neural network function. In addition, the Biobank dataset will permit profiling of sub-groups who show different work-wellbeing relationships and neural network function. Having identified the associations amongst occupational factors, wellbeing, and neural function in the UK Biobank dataset, a second aim of this project is to springboard an external interventional study, in which the same fMRI measures will be assessed in an experiment on different part-time working patterns.

Therefore, the research questions we will be addressing are:
1.	Which regions of the brain show associations of fMRI activation to emotional face perception with employment status, hours worked, shift work, and commuting?
2. Which resting-state fMRI neural networks (‚ÄòNetMats‚Äô) show associations of connectivity strength with employment status, hours worked, shift work, and commuting?
3. Do selected task and resting-state fMRI metrics (taking the most significant results from 1 & 2) mediate relationships between occupational factors and mental health (mental distress, anxiety, happiness and subjective wellbeing)?


$^1$https://whatworkswellbeing.org/category/work
$^2$Work and Wellbeing guide, TUC, 2015
$^3$https://hse.gov.uk/statistics/dayslost.htm


## Hypotheses
---

    #### Description of essential elements:

    1.	Describe the (numbered) hypotheses in terms of directional relationships between your (manipulated or measured) variables. 
    2.	For interaction effects, describe the expected shape of the interactions.
    3.	If you are manipulating a variable, make predictions for successful check variables or explain why no manipulation check is included.


    #### Recommended elements: 

    4.	A figure or table may be helpful to describe complex interactions; this facilitates correct specification of the ordering of all group means. 
    5.	For original research, add rationales or theoretical frameworks for why a certain hypothesis is tested. 
    6.	If multiple predictions can be made for the same IV-DV combination, describe what outcome would be predicted by which theory.

    From van‚Äôt Veer & Giner-Sorolla, 2016


---
---
# Design Plan
---
## Study type

See OSF registration options.

---
## Blinding

Blinding describes who is aware of the experimenta manipulations within a study.

---
## Study design

#### Design specification:
- [ ] Design type (task, rest; event-related, block)	
- [ ] Conditions & Stimuli (detailed as possible, pictures encouraged)	
- [ ] Number of blocks, trials or experimental units per session and/or subject	
- [ ] Timing and Duration (length of each trial and interval between trials)
- [ ] Length of experiment (length of full scan and each run)	
- [ ] Was the design optimized for efficiency, and if so, how?	
- [ ] Presentation software (name, version, operating system; code if possible)	

#### Task specification: 
- [ ] Instructions to subjects (what were they asked to do?) 	
- [ ] Stimuli (what were they; how many were there; did it repeat across trials?)	
- [ ] Stimuli presentation & response collection 	
- [ ] Randomization/pseudo-randomized (why/why not done & how)	
- [ ] Run order (of tasks within scanner)	

---
---
# Sampling Plan
---
## Existing data

Preregistration is designed to make clear the distinction between confirmatory tests, specified prior to seeing the data, and exploratory analyses conducted after observing the data. Therefore, creating a research plan in which existing data will be used presents unique challenges. Please select the description that best describes your situation. 

- [ ] Registration prior to creation of data
- [ ] Registration prior to any human observation of the data
- [x] Registration prior to accessing the data
- [ ] Registration prior to analysis of the data
- [ ] Registration following analysis of the data

---
## Explanation of existing data


If you indicate that you will be using some data that already exist in this study, please describe the steps you have taken to assure that you are unaware of any patterns or summary statistics in the data. This may include an explanation of how access to the data has been limited, who has observed the data, or how you have avoided observing any analysis of the specific data you will use in your study. The purpose of this question is to assure that the line between confirmatory and exploratory analysis is clear.

e.g., links to prior papers, osf project page, prior posters or talks, or descriptions. 

![](https://i.imgur.com/ZXbuxjF.png)

---
## Details of larger study


Is your preregistration part of a larger project?
- [x] Yes
- [ ] No 

        If yes, provide a brief description of the larger study. Note, this does not need to include a list of all measures included in the larger study, but it is meant to provide context for the larger scope of the project.


        If applicable:
        - Link to OSF project page 
        - Link to collaborator‚Äôs related preregistrations, posters, etc. 

        Explanation of how information from larger study or related studies within the larger project have/have not influenced your hypotheses/ measurement decisions. 

---
## Data collection procedures 

Please describe the process by which you will collect your data. For each entry below, you can write a paragraph below as you would for a paper and use the checklist below to keep ensure everything gets done.

- [x] Population	
- [x] Recruitment efforts	
- [ ] Inclusion/Exclusion criteria	
- [x] Clinical criteria: **N/A**
- [x] Matching strategy **N/A**
- [ ] Payment for participation	##??##
- [x] IRB, consent/assent obtained	
- [ ] Number of subjects participated and analyzed	
- [x] Age 	
- [x] Sex	
- [x] Handedness	
- [ ] For group comparisons, what variables (if any) were equated across groups?	
- [ ] Study timeline (e.g., number of visits, length of visits, what was measured/collected at each visit)	


Data are being obtained from the UK Biobank, a population-based cohort study of over 500.000 individuals from across the United Kingdom (Sudlow et al, 2015). Participants, aged 40 to 69, completed baseline asssessments in 2006- 2010. This involved the collection of biological (e.g. blood) and genetic samples, physical measurements, and an extensive questionnaire focusing on the health and lifestyle of individuals, including occupational factors (e.g. nature of employment). Since 2014, a subset of 100.000 individuals are being invited back for the acquisition of brain, body and heart imaging data. As of May 2020, imaging data for 35,501 volunteers has been made available for research. Following approval by the UK Biobank Access Committee (Project ref. no.: ##TBD##), brain imaging data (i.e. task and resting functional brain MRI) were obtained for ##TBD## (##%female##; ##%leftHanded##) participants, together with a curated selection of health and lifestyle factors (see ##InRef## for details).

Ethical approval for the UK Biobank study was granted by the NHS National Research Ethics Service North West (Ref. no.: 11/NW/0382). 



---
## Sample size & Stopping rule


Effect size: 	
> **value**
 
Source of predicted effect size (prior lit, pilot etc.):
> **value**
 
Significant level:
> **value**
 
Target power:
> **value**
 
Specify the type of outcome used as the basis of power computations, e.g. signal in a pre¬≠specified ROI, or whole image voxelwise (or cluster¬≠wise, peak¬≠wise, etc.):	
> **value**
---
---
# Variables
---
## Manipulated behavioural variables 

i.e. Indepenent Variables. This section should be considered optional and might be unnecessary depending on the information covered in the previous sections.

---
## Measured behavioural variables

- Describe each variable that you will measure. You do not need to include any variables that you plan on collecting if they are not going to be included in the confirmatory analyses of this study.

- Outcome measures (specific measure, scale/range of measure, which subscale/component of measure you will use): 

- Predictor measures (specific measure, scale/range of measure, which subscale/component of measure you will use):

- Covariate measures (specific measure, scale/range of measure, which subscale/component of measure you will use):

- How was behavioral task performance measured (if task fMRI; e.g., response time, accuracy)?

- Contingency plans for behavioral analysis (e.g., plans if x% of behavioral data is missing; poor variability in behavioral measure). 

`e.g.:` If the X questionnaire is missing for more than 10% of participants we will not use it or if X 	does not show variability in response (either ceiling or floor effects) in which we cannot look at 	behavioral pattern of interest, we will not use that questionnaire and use Y questionnaire instead.

---
## Indices

Derived indices from fMRI data
`e.g.:`Contrast masks and how they were obtained.

This is an optional section, and depending on the information covered in the previous sections it might be unnecessary.

---
## Additional operational definitions

Region Specificity (e.g., defined based on anatomical definition, Prior study cluster, Neurosynth definition (make sure to be specific here!), Parcellation definition)

Any other definitions used across study: (e.g., how is ‚Äúrisk‚Äù defined; how was ‚Äúdepressed‚Äù)


---
---
# Analysis Plan
---
## Transformations 

If you plan on transforming, centering, recoding the data, or will require a coding scheme for categorical variables, please describe that process.

Contingency plans for transformation: (e.g., transformations that will occur if data are skewed or for model convergence/multicollinearity) 

Code, if applicable: for scoring behavioral data

---
## Data exclusion

How will you determine which data points or samples (if any) to exclude from your analyses? How will outliers be handled?

If any subjects were/will be scanned but then rejected/could be rejected from analysis after data collection, state reasons for rejection/possible rejections.
	(e.g., If a participant has X percentage of volumes with motion, participant will be excluded)
	Contingency plans: (e.g., plans for missing field map, plans for dropout, missing mprage etc.)

How will you deal with incomplete or missing data (e.g., missing timepoints or missing/incomplete data within or between runs; what percent missing will be included)?


---
## Data acquisition
(details below from [UK Biobank Imaging documentation](https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/brain_mri.pdf), section `2. Image Acquisition Protocols`)


#### Subject preparation:
- [ ] Mock scanning (Report type of mock scanner and protocol; i.e. duration, types of simulated scans, experiments).	
- [ ] Specific accommodations (e.g., pediatric, parent present? Asleep?) 	
- [ ] Experimental personnel (number of planned personnel to interact with subjects)	

#### MRI system:
- [x] Manufacturer, field strength (in Tesla), model name	

#### MRI acquisition:
- [ ] Pulse sequence (gradient/spin echo etc.)	
- [x] Image type (EPI, spiral, 3D etc.)	

**Essential sequence & imaging parameters.**
*For all acquisitions:*
- [ ] Echo time (TE).
- [ ] Repetition time (TR).
    - [ ] For multi¬≠shot acquisitions, additionally the time per volume.
- [ ]  Flip angle (FA).
- [ ]  Acquisition time (duration of acquisition). 
 
*Functional MRI:*
- [ ] Number of volumes.
- [ ] Sparse sampling delay (delay in TR) if used. 

*Inversion recovery sequences:*
- [ ] Inversion time (TI). 

*B0 field maps:*
- [ ] Echo time difference (dTE). 
- [ ] Diffusion MRI:
    - [ ] Number of directions.
    - [ ] Direction optimization, if used and type.
- [ ] b-values.
- [ ] Number of b=0 images.
- [ ] Number of averages (if any).
- [ ] Single shell, multi-shell (specify equal or unequal spacing).
- [ ] Single- or dual-spin-echo, gradient mode (serial or parallel).
- [ ] If cardiac gating used.

*Imaging parameters:*
- [ ] Field of view.
- [ ] In-plane matrix size, slice thickness and interslice gap, for 2D acquisitions. 
- [ ] Slice orientation:
    - [ ] Axial, sagittal, coronal or oblique.
    - [ ] Angulation: If acquistion not aligned with scanner axes, specify angulation to AC¬≠PC line (see Slice position procedure). 
- [ ] 3D matrix size, for 3D acquisitions.	
- [ ] Phase encoding	
- [ ] Parallel imaging method & parameters	
- [ ] Multiband parameters	
- [ ] Readout parameters 	
- [ ] Fat suppression (for anatomical, state if used)	
- [ ] Shimming	
- [ ] Slice order & timing	
- [ ] Brain coverage (e.g., whole brain, was cerebellum, brain stem included)
- [ ] Scanner-side preprocessing (e.g., Including: Reconstruction matrix size differing from acquisition matrix size; Prospective-motion correction (including details of any optical tracking, and how motion parameters are used); Signal inhomogeneity correction; Distortion-correction.)	
- [ ] Scan duration (in seconds)	
- [ ] Other non-standard procedures	
- [ ] T1 stabilization (discarded ‚Äúdummy‚Äù scans acquired discarded by scanner)	
- [ ] Diffusion MRI gradient table (Also referred to as the b¬≠matrix, but not to be confused with the 3√ó3 matrix that describes diffusion weighting for a single diffusion weighted measurement)	

#### 1. Brain imaging hardware

The scanner used for the acquisition of brain imaging data is a standard Siemens Skyra 3T running VD13A SP4 (as of October 2015), with a standard Siemens 32-channel RF receiver head coil. The data is collected in three identical centres dedicated to UK Biobank imaging in Manchester, Newcastle, and Reading. 

#### 2. Echo-planar imaging

The EPI-based acquisitions (rfMRI and tfMRI) utilize simultaneous multi-slice (multiband) acceleration (Larkman et al., 2001, Moeller et al., 2010). Biobank uses pulse sequences and reconstruction code from the Center for Magnetic Resonance Research (CMRR), University of Minnesota https://www.cmrr.umn.edu/multiband. These developments were partially generated as part of the Human Connectome Project (HCP, NIH grant 1U54MH091657), as described in (Ugurbil et al., 2013). The fMRI data and primary dMRI data are all acquired with AP (anterior-posterior) phase encoding direction.

Distortion correction of EPI requires an estimate of the static field map. This fieldmap is derived from pairs of spin-echo EPI acquisitions with opposite phase encoding directions, acquired as part of the dMRI dataset; in addition to the primary dMRI data, 3 $B_0$ images are acquired with reversed phase encoding for later fieldmap estimation (along with 3 $B_0$ images with standard phase encoding). The estimated fieldmap is used for distortion correction in both the dMRI and fMRI datasets. This aproach was found to have similar accuracy to separate fieldmap acquisitions in much shorter time and with greater robustness against head motion.

##### 3. Setup::shimming [2 min]

It is critical to achieve maximally consistent spatial coverage of scans in the presence of differences in subject positioning and head size. For each scan, the field-of-view is automatically determined based on Siemens‚Äô auto-align software, which aligns a scout scan to an atlas. In the infrequent situation where auto-align failed, alignment was set by the radiographer. T1 and T2 structurals are acquired using straight sagittal orientation (i.e., with the field-of-view aligned to the scanner axes). fMRI (task and resting-state). Using the population brain size and shape results from (Mennes et al., 2014), imaging matrix is angled such that the front of the brain is tilted down (relative to the imaging matrix) by 16$^{\circ}$, with respect to the AC-PC line.

Shim field accuracy is critical for data quality, and was found to be suboptimal when using default settings on the MRI scanner, particularly for the simultaneous multi-slice EPI acquisitions. Initially, shim quality was improved by manually iterating the shimming process 3 times; this process which was later replaced by a single shim using a reduced shimming field-of-view, thereby improving resolution of the acquired field map. The scans are prescribed to avoid any subsequent re-shimming during the entire protocol.


##### 4. T1-weighted structural imaging [5 min]

Resolution: 1x1x1 mm
Field-of-view: 208x256x256 matrix
Duration: 5 minutes
3D MPRAGE, sagittal, in-plane acceleration iPAT=2, prescan-normalise

The superior-inferior field-of-view is large (256mm), at little cost, in order to include reasonable amounts of neck/mouth, as those areas will be of interest to some researchers.

##### 5. Resting-state functional (rf)MRI [6 min:490 timepoints]

Resolution: 2.4x2.4x2.4 mm
Field-of-view: 88x88x64 matrix
TR: 0.735 s
TE: 39ms
GE-EPI with x8 multislice acceleration, no iPAT, flip angle 52, fat saturation

As implemented in the CMRR multiband acquisition, a separate ‚Äúsingle-band reference scan‚Äù is also acquired. This has the same geometry (including EPI distortion) as the timeseries data, but has higher between-tissue contrast to noise, and is used as the reference scan in head motion correction and alignment to other modalities.

##### 6. Task functional (tf)MRI [4 min:332 timepoints]

Acquisition details are identical to those used for rfMRI, with the exception of the duration (i.e. 4 min vs 6 min),

The task is the Hariri faces/shapes ‚Äúemotion‚Äù task (Hariri et al., 2002, Barch et al., 2013), as implemented in the HCP, but with shorter overall duration and hence fewer total stimulus block repeats. The participants are presented with blocks of trials and asked to decide either which of two faces presented on the bottom of the screen match the face at the top of the screen, or which of two shapes presented at the bottom of the screen match the shape at the top of the screen. The faces have either angry or fearful expressions.

The ePrime script that controls the video presented to the participant is derived from the one used by the HCP, and is available at http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=1462.

##### 7. T2-weighted FLAIR structural imaging [6 min]

Resolution: 1.05x1x1 mm
Field-of-view: 192x256x256 matrix
Duration: 6 minutes

3D SPACE, sagittal, in-plane acceleration iPAT=2, partial Fourier = 7/8, fat saturation, elliptical k-space scanning, prescan-normalise


After early piloting, a standard T2/PD-weighted acquisition was dropped due to a combination of factors such as overall value and timing practicalities. However a T2-weighted FLAIR image is acquired, which is generally of good quality and which shows strong contrast for white matter hyperintensities.

##### Compatibility across different phases of imaging

The imaging documentation reads:

    Ideally the imaging protocol will stay fixed over time. However, early improvements in the dMRI and T2_FLAIR protocols werefound to be very valuable, resulting in significant enough data improvements to outweigh the priority of holding things perfectlyconstant (and taking into account the relatively small numbers of datasets affected). This change was made at the start of protocol ‚ÄúPhase 3‚Äù; the different phases are described in detail below. A variable available in the UK Biobank database (Acquisition protocol phase) specifies which protocol phase (currently from 1 to 5) was used for a given subject.

We're not getting dMRI or T2_Flair, so for our purposes there is no difference between acquisision phases.

---
## Preprocessing

For each sub-section below, you can write a paragraph below as you would for a paper and use the checklist below to keep ensure everything gets done.

#### Preliminary quality control:
- [ ] Motion monitoring (For functional or diffusion acquisitions, any visual or quantitative checks for severe motion; likewise, for structural images, checks on motion or general image quality.)	
- [ ] Incidental findings (Protocol for review of any incidental findings, and how they are handled in particular with respect to possible exclusion of a subject‚Äôs data.)	

#### Preprocessing::Notes
- [ ] For each piece of software used, give the version number (or, if no version number is available, date of last application of updates)	
- [ ] If any subjects required different processing operations or settings in the analysis, those differences should be specified explicitly

#### Pre-processing::General
- [ ] Specify order of preprocessing operations	
- [ ] Describe any data quality control measures	
- [ ] Unwarping of B0 distortions	
- [ ] Slice timing correction	
- [ ] Reference slice and type of interpolation used (e.g., ‚ÄúSlice timing correction to the first slice as performed, using SPM5's Fourier phase shift interpolation‚Äù)	
- [ ] Motion correction	
- [ ] Reference scan, image similarity metric, type of interpolation used, degrees-of-freedom (if not rigid body) and, ideally, optimization method, e.g., ‚ÄúHead motion corrected with FSL's MCFLIRT by maximizing the correlation ratio between each timepoint and the middle volume, using linear interpolation.‚Äù	
- [ ] Motion susceptibility correction used	
- [ ] Smoothing (i.e. Size and type of smoothing kernel - provide justification for size; e.g., for a group study, ‚Äú12 mm FHWM Gaussian smoothing applied to ameliorate differences in intersubject localization‚Äù; for single subject fMRI ‚Äú6 mm FWHM Gaussian smoothing used to reduce noise‚Äù)
	

#### Inter-subject registration:

- [ ] Intersubject registration method used	
- [ ] Illustration of the voxels present in all subjects (‚Äúmask image‚Äù) can be helpful, particularly for restricted fields of view (to illustrate overlap of slices across all subjects). Better still would be an indication of average BOLD sensitivity within each voxel in the mask	
- [ ] Transformation model and optimization	
- [ ] Transformation model (linear/affine, nonlinear), type of any non-linear transformations (polynomial, discrete cosine basis), number of parameters (e.g., 12 parameter affine, 3 √ó 2 √ó 3 DCT basis), regularization, image-similarity metric, and interpolation method	
- [ ] Object image information (image used to determine transformation to atlas)	
- [ ] Anatomical MRI? Image properties (see above)	
- [ ] Co-planar with functional acquisition?	
- [ ] Functional acquisition co-registered to anatomical? if so, how?	
- [ ] Segmented gray image?	
- [ ] Functional image (single or mean)	
- [ ] Atlas/target information	
- [ ] Brain image template space, name, modality and resolution (e.g., ‚ÄúFSL's MNI Avg152, T1 2 √ó 2 √ó 2 mm‚Äù; ‚ÄúSPM2's MNI gray matter template 2 √ó 2 √ó 2 mm‚Äù)	
- [ ] Coordinate space (Typically MNI, Talairach, or MNI converted to Talairach. If MNI converted to Talairach, what method? e.g., Brett's mni2tal?How were anatomical locations [e.g., gyral anatomy, Brodmann areas] determined? [e.g., paper atlas, Talairach Daemon, manual inspection of individuals' anatomy, etc.])

- [ ] Smoothing (Size and type of smoothing kernel - provide justification for size; e.g., for a group study, ‚Äú12 mm FHWM Gaussian smoothing applied to ameliorate differences in intersubject localization‚Äù; for single subject fMRI ‚Äú6 mm FWHM Gaussian smoothing used to reduce noise‚Äù)
	

---
## Statistical modelling

Planned comparison 
If the experiment has multiple conditions, what are the specific planned comparisons, or is an omnibus ANOVA used?

General issues
For novel methods that are not described in detail in a separate paper, provide explicit description and validation of method.

For each sub-section below, you can write a paragraph below as you would for a paper and use the checklist below to keep ensure everything gets done.

#### First level (fx) modelling

- [ ] Event-related design predictors.
    - [ ] Modeled duration, if other than zero.
    - [ ] Parametric modulation.	
- [ ] Block Design predictors. (Note whether baseline was explicitly modeled.)	

HRF basis, typically one of: 
- [ ] Canonical only.
- [ ] Canonical plus temporal derivative.
- [ ] Canonical plus temporal and dispersion derivative. Smooth basis (e.g. SPM ‚Äúinformed‚Äù or Fourier basis; FSL‚Äôs FLOBS).
- [ ] Finite Impulse Response model.
	
- [ ] Drift regressors (e.g. DCT basis in SPM, with specified cut-off).	
- [ ] Movement regressors; specify if squares and/or temporal derivative used.	
- [ ] Any other nuisance regressors, and whether they were entered as interactions (e.g. with a task effect in 1st level fMRI, or with group effect).	
- [ ] Any orthogonalization of regressors, and set of other regressors used to orthogonalize against.	
- [ ] Contrast construction (Exactly what terms are subtracted from what? Define these in terms of task or stimulus conditions (e.g., using abstract names such as AUDSTIM, VISSTIM) instead of underlying psychological concepts.
	
- [ ] Autocorrelation model type (e.g., AR(1), AR(1) + WN, or arbitrary autocorrelation function), and whether global or local.	 (e.g., for SPM2/SPM5, ‚ÄòApproximate AR(1) autocorrelation model estimated at omnibus F-significant voxels (P < 0.001), used globally over the whole brain‚Äô; for FSL, ‚ÄòAutocorrelation function estimated locally at each voxel, tapered and regularized in space.‚Äô).	


#### Second level (group) modelling
- [ ] Statistical model and estimation method, inference type (mixed/random effects or fixed), e.g., ‚ÄúMixed effects inference with one sample t-test on summary statistic‚Äù (SPM2/SPM5), e.g., ‚ÄúMixed effects inference with Bayesian 2-level model with fast approximation to posterior probability of activation.‚Äù (FSL). If fixed effects inference used, justify	
- [ ] If more than 2-levels, describe the levels and assumptions of the model (e.g., are variances assumed equal between groups)		
- [ ] Repeated measures? If multiple measurements per subject, list method to account for within subject correlation, exact assumptions made about correlation/variance	e.g., SPM: ‚ÄúWithin-subject correlation estimated at F-significant voxels (P <0.001), then used globally over whole brain‚Äù; or, if variances for each measure are allowed to vary, ‚ÄúWithin-subject correlation and relative variance estimated‚Ä¶‚Äù	
- [ ] For group model with repeated measures, specify:
    - [ ] How condition effects are modeled (e.g. as factors, or as linear trends).
    - [ ] Whether subject effects are modeled (i.e. as regressors, as opposed to with a covariance structure).	
- [ ] For group effects: clearly state whether or not covariates are split by group (i.e. fit as a group¬≠by¬≠covariate interaction).	
- [ ] Model type
 (Some suggested terms include:
- ‚ÄúMass Univariate‚Äù.
- ‚ÄúMultivariate‚Äù (e.g. ICA on whole brain data).
- ‚ÄúMass Multivariate‚Äù (e.g. MANOVA on diffusion or morphometry tensor data).
- ‚ÄúLocal Multivariate‚Äù (e.g. ‚Äúsearchlight‚Äù).
- ‚ÄúMultivariate, intra¬≠subject predictive‚Äù (e.g. classify individual trials in event-related fMRI).
- ‚ÄúMultivariate inter¬≠subject predictive‚Äù (e.g. classify subjects as patient vs. control).
- ‚ÄúRepresentational Similarity Analysis‚Äù.)	
- [ ] Model settings (The essential details of the model. For mass¬≠univariate, first level fMRI, these include:
    - [ ] Drift model, if not already specified as a dependent variable (e.g. locally linear detrending of data & regressors, as in FSL).
    - [ ] Autocorrelation model (e.g. global approximate AR(1) in SPM; locally regularized autocorrelation function in FSL).
For mass¬≠univariate second level fMRI these include:
- [ ] Fixed effects (all subjects‚Äô data in one model).
- [ ] Random or mixed¬≠effects model, implemented with:
    - [ ] Ordinary least squares (OLS, aka unweighted summary statistics approach; SPM default, FSL FEAT‚Äôs ‚ÄúSimple OLS‚Äù).
    - [ ] Weighted least squares (i.e. FSL FEAT‚Äôs ‚ÄúFLAME 1‚Äù), using voxel-wise estimate of between subject variance.
    - [ ] Global weighted least squares (i.e. SPM‚Äôs MFX).
With any group (multi¬≠subject) model, indicate any specific variance structure, e.g.
- Unequal variance between groups (and if globally pooled, as in SPM).
- If repeated measures, the specific covariance structure assumed (e.g. compound symmetric, or arbitrary; if globally pooled).
For local multivariate report:
- [ ] The number of voxels in the local model.
- [ ] Local model used (e.g. Canonical Correlation Analysis) with any constraints (e.g. positive weights only).	

#### ROI analysis
- [ ] How were ROIs defined	(e.g., functional, anatomical, parcel localizer)?
- [ ] How was signal extracted within ROI? (e.g., average parameter estimates, FIR deconvolution?)		
- [ ] If percent signal change reported, how was scaling factor determined (e.g., height of block regressor or height of isolated event regressor)?	
- [ ] Is change relative to voxel-mean, or whole-brain mean?	
- [ ] Justify definition of ROI and analysis conducted with it: (e.g., if your ROI is defined based on the cluster;  how will you ensure your ROI analyses are not circular?)	

If not previously specified above, what statistical model will you use to test each hypothesis? Please include the type of model (e.g. ANOVA, multiple regression, SEM, etc) and the specification of the model (this includes each variable that will be included as predictors, outcomes, or covariates). Please specify any interactions that will be tested and remember that any test not included here must be noted as an exploratory test in your final article. 

---
## Statistical inference

For each sub-section below, you can write a paragraph below as you would for a paper and use the checklist below to keep ensure everything gets done.

#### Inference on statistic image (i.e. thresholding)
- [ ] Search region (Type of search region for analysis, and the volume in voxels or CC)
	- If not whole brain, state how region was determined; method for constructing region should be independent of present statistic image	
    - Whole brain or ‚Äúsmall volume‚Äù; carefully describe any small volume correction used for each contrast.
    - If a small-volume correction mask is defined anatomically, provide named anatomical regions from a publicly available ROI atlas.
    - If small-volume correction mask is functionally defined, clearly describe the functional task and identify any risk of circularity.
    - All small-volume corrections should be fully described in the methods section, not just mentioned in passing in the results.	
- [ ] Statistic used for thresholding:
    - Voxel-wise (aka peak¬≠wise in SPM).
    - Cluster-wise.
    - Cluster size.
    - Cluster mass.
    - Threshold¬≠free Cluster Enhancement (TFCE).

For cluster size or mass, report: 
- Cluster-forming threshold.
For all cluster¬≠wise methods, report:
- Neighborhood size used to form clusters (e.g. 6, 18 or 26).
For TFCE, report:
- Use of non¬≠default TFCE parameters.)	
- [ ] P value computation (Report if anything but standard parametric inference used to obtain (uncorrected) P¬≠values. If nonparametric method was used, report method (e.g. permutation or bootstrap) and number of permutations/samples used.)	
- [ ] Multiple test correction (For mass¬≠univariate, specify the type of correction and how it is obtained, especially if not the typical usage.):
    - Familywise Error.
        - Random Field Theory (typical). 
        - Permutation.
        - Monte Carlo.
        - Bonferroni.
    - False Discovery Rate.
        - Benjamini & Hochberg FDR (typical). 
        - Positive FDR.
        - Local FDR.
        - Cluster¬≠level FDR.
    - None/Uncorrected.

If permutation or Monte Carlo, report the number of permutations/samples. If Monte Carlo, note the brain mask and smoothness used, and how smoothness was estimated.

If correction is limited to a small volume, the method for selecting the region should be stated explicitly.	

If no formal multiple comparisons method is used, the inference must be explicitly labeled ‚Äúuncorrected.‚Äù	

If FWE found by random field theory list the smoothness in mm FWHM and the RESEL count	
If FWE found by simulation (e.g., AFNI AlphaSim), provide details of parameters for simulation	
If not a standard method, specify the method for finding significance (e.g., ‚ÄúCustom in-lab software was used to construct statistic maps and thresholded at FDR< 0.05 (Benjamini and Hochberg, 1995)‚Äù	
If cluster-wise significance, state cluster-defining threshold (e.g., P = 0.001)	

- [ ] False negative discussion	
Any discussion of failure to reject the null hypothesis (e.g., lack of activation in a particular region) should be accompanied by SNR or effect size of the actually observed effect (allows reader to infer power to estimate an effect)	

#### Functional Connectivity
*Confound adjustment & filtering* 
- [ ] Method for detecting movement artifacts, movement-related variation, and remediation (e.g. ‚Äòscrubbing‚Äô, ‚Äòdespiking‚Äô, etc). 
- [ ] Use of global signal regression, exact type of global signal used and how it was computed. 
- [ ] Whether a high or lowpass temporal filtering is applied to data, and at which point in the analysis pipeline. Note, any temporal regression model using filtered data should have its regressors likewise filtered.	

*Multivariate method: Independent Component Analysis*
- [ ] Algorithm to estimate components.
- [ ] Number of components (if fixed), or algorithm for estimating number of components.
- [ ] If used, method to synthesize multiple runs.
- [ ] Sorting method of IC‚Äôs, if any.
- [ ] Detailed description of how components were chosen for further analysis.   	 

*Dependent variable definition* 
For seed-based analyses report: 
- [ ] Definition of the seed region(s). 
- [ ] Rationale for choosing these regions. 
For region-based analyses report:
- [ ] Number of ROIs.
- [ ] How the ROI‚Äôs are defined (e.g. citable anatomical atlas; auxiliary fMRI experiments); note if ROIs overlap.
- [ ] Assignment of signals to regions (i.e. how a time series is obtained from each region, e.g. averaging or first singular vector)
- [ ]  Note if considering only bilateral (L+R) merged regions.
- [ ] Note if considering only interhemispheric homotopic connectivity. 
	 
*Functional connectivity measure/ model*
- [ ] Measure of dependence used, e.g. Pearson‚Äôs (full) correlation, partial 
correlation, mutual information, etc; also specify: 
    - [ ] Use of Fisher‚Äôs Z-transform (Yes/No) and, if standardised, effective  N is used to compute standard error (to account for any filtering 
operations on the data). 
    - [ ] Estimator used for partial correlation. 
    - [ ] Estimator used for mutual information. 
- [ ] Regression model used to remove confounding effects (Pearson or partial correlation).	

*Effectivity connectivity*
- [ ] Model. 
- [ ] Algorithm used to fit model.
- [ ] If per¬¨ subject model, method used to generalize inferences to population. 
- [ ] Itemize models considered, and method used for model comparison.
	
*Graph analysis*
- [ ] Report the ‚Äòdependent variable‚Äô and ‚Äòfunctional connectivity measure‚Äô used (see above). 
Specify either: 
- Weighted graph analysis or, 
- Binarized graph analysis is used, clarifying the method used for thresholding (e.g. a 10% density threshold, or a statistically defined threshold); consider the sensitivity of your findings to the particular choice of threshold used. 
- [ ] Itemise the graph summaries used (e.g. clustering coefficient, efficiency, etc), whether these are global or per¬¨node/per¬¨edge summaries. In particular with fMRI or EEG, clarify if measures applied to individual subject networks or group networks.
	


---
## Follow-up analyses
 
If not specified previously, will you be conducting any confirmatory analyses to follow up on effects in your statistical model, such as subgroup analyses, pairwise or complex contrasts, or follow-up tests from interactions? Remember that any analyses not specified in this research plan must be noted as exploratory.
 
---
## Exploratory analyses

If you plan to explore your data set to look for unexpected differences or relationships, you may describe those tests here. An exploratory test is any test where a prediction is not made up front, or there are multiple possible tests that you are going to use. A statistically significant finding in an exploratory test is a great way to form a new confirmatory hypothesis, which could be registered at a later time.

###### tags: `raeBiobank` `github` `mainRepo` `RR`
